Jefferies: IPCM Still In The Sweet Spot

Jefferies reports that IPC The Hospitalist Company IPCM remains well-positioned to benefit from increasing hospitalist demand in the acute and sub-acute sectors. “The company has ample liquidity to continue making accretive acquisitions,” Jefferies writes. “And while the stock's momentum may slow down NT given its recent run, the LT outlook remains extremely favorable. Reiterate Buy/$46PT.” IPC The Hospitalist Company closed Tuesday at $40.80.